Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
Status:
Completed
Trial end date:
2018-02-24
Target enrollment:
Participant gender:
Summary
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period
cross-over study in asthma patients. The study consisted of a 14-day screening period,
followed by a 14-day run-in period, and a treatment epoch which consists of three treatment
periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods)
by a wash-out period. The duration of each treatment period may be extended up to a duration
of 18 days if needed for operational reasons. The third treatment period was followed by a
Study Completion evaluation at 1-7 days following the last dose. The treatment periods were
separated by wash-out periods of 14 to 21 days duration.